Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
MORRISTOWN, New Jersey, June 15, 2026 (GLOBE NEWSWIRE) — Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced that it has appointed Sahil V. Kirpekar, M.D., as President, Chief Executive Officer and a member of Reunion’s Board of Directors, succeeding Greg Mayes in these positions effective immediately. Dr. Kirpekar is a trained physician who brings two decades of experience in the health sciences, focusing on commercial strategy, business development, capital markets, company building, and clinical-stage value creation. He joins Reunion at a pivotal moment as the company builds on positive postpartum depression clinical data, and expands the reach of luvesilocin into multiple psychiatric indications, with Phase 2 trials underway in adjustment disorder and generalized anxiety disorder.
